But Pfizer also cut its full-year revenue and profit forecast, blaming a stronger dollar.
"The only thing that they lowered their guidance on ... was all currency," Leerink Partners Pharma Analyst Seamus Fernandez told CNBC. "It's currency effects. We saw it with J&J ... and Lilly last week."
Pfizer reported first-quarter adjusted profit of 51 cents per share on $10.86 billion in revenue—helped by demand for its vaccines and cancer drugs.
Shares of the drugmaker were roughly unchanged at $34.62 in premarket trading. The stock rose about 12 percent in the three months to March 31, while the broader Dow industrial average fell 1.45 percent.